MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/ard-2023-224670

Медицинская библиотека · Annals of the rheumatic diseases · 2024

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).

Aymon Romain, Mongin Denis, Bergstra Sytske Anne, Choquette Denis, Codreanu Catalin, De Cock Diederik, Dreyer Lene, Elkayam Ori, Huschek Doreen, Hyrich Kimme L, Iannone Florenzo, Inanc Nevsun, Kearsley-Fleet Lianne, Koca Suleyman Serdar, Kvien Tore K, Leeb Burkhard F, Lukina Galina, Nordström Dan C, Pavelka Karel, Pombo-Suarez Manuel, Rodrigues Ana, Rotar Ziga, Strangfeld Anja, Verschueren Patrick, Westermann Rasmus, Zavada Jakub, Courvoisier Delphine Sophie, Finckh Axel, Lauper Kim

Наблюдательное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis factor inhibitors (TNFi) adalimumab or etanercept.

OBJECTIVE

Compare treatment discontinuations for adverse events (AEs) among second-line therapies in an international real-world RA population.

METHODS

Patients initiating JAKi, TNFi or a biological with another mode of action (OMA) from 17 registers participating in the 'JAK-pot' collaboration were included. The primary outcome was the rate of treatment discontinuation due to AEs. We used unadjusted and adjusted cause-specific Cox proportional hazard models to compare treatment discontinuations for AEs among treatment groups by class, but also evaluating separately the specific type of JAKi.

RESULTS

Of the 46 913 treatment courses included, 12 523 were JAKi (43% baricitinib, 40% tofacitinib, 15% upadacitinib, 2% filgotinib), 23 391 TNFi and 10 999 OMA. The adjusted cause-specific hazard rate of treatment discontinuation for AEs was similar for TNFi versus JAKi (1.00, 95% CI 0.92 to 1.10) and higher for OMA versus JAKi (1.11, 95% CI 1.01 to 1.23), lower with TNFi compared with tofacitinib (0.81, 95% CI 0.71 to 0.90), but higher for TNFi versus baricitinib (1.15, 95% CI 1.01 to 1.30) and lower for TNFi versus JAKi in patients 65 or older with at least one cardiovascular risk factor (0.79, 95% CI 0.65 to 0.97).

CONCLUSION

While JAKi overall were not associated with more treatment discontinuations for AEs, subgroup analyses suggest varying patterns with specific JAKi, such as tofacitinib, compared with TNFi. However, these observations should be interpreted cautiously, given the observational study design.

Для цитирования: Aymon Romain, Mongin Denis, Bergstra Sytske Anne, Choquette Denis, Codreanu Catalin, De Cock Diederik, Dreyer Lene, Elkayam Ori, Huschek Doreen, Hyrich Kimme L, Iannone Florenzo, Inanc Nevsun, Kearsley-Fleet Lianne, Koca Suleyman Serdar, Kvien Tore K, Leeb Burkhard F, Lukina Galina, Nordström Dan C, Pavelka Karel, Pombo-Suarez Manuel, Rodrigues Ana, Rotar Ziga, Strangfeld Anja, Verschueren Patrick, Westermann Rasmus, Zavada Jakub, Courvoisier Delphine Sophie, Finckh Axel, Lauper Kim. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).. Annals of the rheumatic diseases. 2024. DOI: 10.1136/ard-2023-224670.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.